FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study.

Cancer Sci · 2026 · PMC13134512 · PMID 41795872

Europe PMC DOI

hedged sentence

0.0770

closest p · 1.5× alpha

0.0770

boldest claim

The sentences

showed a trendp = 0.077so close (0.05 < p ≤ 0.1)

Treatment Outcomes in the Overall Population and by Treatment Sequence In the overall population, GnP showed a trend toward longer OS compared with FFX in the unadjusted analysis (median OS: 19.4 months vs. 19.1 months; HR, 0.93 [95% CI: 0.85–1.01]; p = 0.077; Figure 2A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.